AU2003217916A1 - Stable formulations of angiotensin converting enzyme (ace) inhibitors - Google Patents

Stable formulations of angiotensin converting enzyme (ace) inhibitors

Info

Publication number
AU2003217916A1
AU2003217916A1 AU2003217916A AU2003217916A AU2003217916A1 AU 2003217916 A1 AU2003217916 A1 AU 2003217916A1 AU 2003217916 A AU2003217916 A AU 2003217916A AU 2003217916 A AU2003217916 A AU 2003217916A AU 2003217916 A1 AU2003217916 A1 AU 2003217916A1
Authority
AU
Australia
Prior art keywords
ace
inhibitors
converting enzyme
angiotensin converting
stable formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003217916A
Other versions
AU2003217916A8 (en
Inventor
Robert Gwozdz
John C. James
Christopher L. Pelloni
Scott Stofik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceuticals USA Inc
Publication of AU2003217916A8 publication Critical patent/AU2003217916A8/en
Publication of AU2003217916A1 publication Critical patent/AU2003217916A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003217916A 2002-03-08 2003-03-06 Stable formulations of angiotensin converting enzyme (ace) inhibitors Abandoned AU2003217916A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9384902A 2002-03-08 2002-03-08
US10/093,849 2002-03-08
PCT/US2003/006606 WO2003075842A2 (en) 2002-03-08 2003-03-06 Stable formulations of angiotensin converting enzyme (ace) inhibitors

Publications (2)

Publication Number Publication Date
AU2003217916A8 AU2003217916A8 (en) 2003-09-22
AU2003217916A1 true AU2003217916A1 (en) 2003-09-22

Family

ID=27804229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003217916A Abandoned AU2003217916A1 (en) 2002-03-08 2003-03-06 Stable formulations of angiotensin converting enzyme (ace) inhibitors

Country Status (2)

Country Link
AU (1) AU2003217916A1 (en)
WO (1) WO2003075842A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20080234353A1 (en) 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
ES2603856T3 (en) * 2004-03-29 2017-03-01 Les Laboratoires Servier Procedure for preparing a solid pharmaceutical composition
SI21800A (en) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
RS53324B (en) 2005-11-17 2014-10-31 Silverstone Pharma Est. Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
DE602006000402T8 (en) * 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stable preparation containing a moisture-sensitive active substance and process for the preparation of the preparation.
MX2008015343A (en) * 2006-06-02 2008-12-16 Teva Pharma Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof.
US20100035955A1 (en) * 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
MX2009000358A (en) * 2006-07-10 2009-01-27 Teva Pharma Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof.
WO2009053994A1 (en) * 2007-10-26 2009-04-30 Matrix Laboratories Limited Process for preparing pure amorphous quinapril hydrochloride
MX365621B (en) 2011-12-21 2019-06-07 Elanco Tiergesundheit Ag New combination.
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600120D0 (en) * 1996-01-15 1996-01-15 Astra Ab Novel medical use

Also Published As

Publication number Publication date
AU2003217916A8 (en) 2003-09-22
WO2003075842A3 (en) 2004-01-08
WO2003075842A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AU2003282920A1 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
AU2003220401A1 (en) Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
AU2003261434A1 (en) Iminothiazolidinones as inhibitors of hcv replication
AU2003298514A1 (en) Methods and compositions using cholinesterase inhibitors
AU2002953073A0 (en) Amplification of biotin-mediated targeting
WO2003063797A8 (en) Cycloalkyl inhibitors of potassium channel function
AU2003209321A1 (en) Substituted pyridazinones as inhibitors of p38
AU2002357312A1 (en) Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
AU2003211093A1 (en) Inhibitors of rgs proteins
AU2003217105A1 (en) Novel of cytokine inhibitors
AU2003261319A1 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
AU2003300692A1 (en) Stable formulations of ace inhibitors and methods for preparation thereof
AU2003217916A1 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
AU2003277674A1 (en) Novel parp inhibitors
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)
AU2003218969A1 (en) Modulation of t lymphocytes using dp iv inhibitors
AU2003237983A1 (en) Derivatives of azepine and thiazeran as interleukin converting enzyme inhibitors
AU2003301903A1 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
AU2002365132A1 (en) BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-Alpha CONVERTING ENZYME (TACE)
AU2002306734A1 (en) Inhibitors of plasmepsins
AU2003290417A1 (en) Process for the preparation of angiotensin converting enzyme (ace) inhibitors and its use
AU2003238215A1 (en) Novel interleukin-1 beta converting enzyme inhibitors
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2003237981A1 (en) NOVEL INTERLEUKIN-1Beta CONVERTING ENZYME INHIBITORS
AU2002316552A1 (en) Inhibitor of t cell activation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase